Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo

Volume: 331, Pages: 112 - 121
Published: Oct 1, 2020
Abstract
Roxadustat is the first orally administered, small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that has been submitted for FDA regulatory approval to treat anemia secondary to chronic kidney diseases. Its usage has also been suggested for pulmonary fibrosis; however, the corresponding therapeutic effects remain to be investigated. The in vitro effects of roxadustat on cobalt chloride (CoCl2)-stimulated pulmonary fibrosis...
Paper Details
Title
Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo
Published Date
Oct 1, 2020
Volume
331
Pages
112 - 121
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.